Lilly China Announces Leadership Reshuffle and Highlights Strong Product Pipeline Amid Market Expansion

According to the "Pharmaceutical Representative" report, on September 14, Eli Lilly China announced that Ping Yuan, the current acting head of the Diabetes Alliance Business Unit, has been appointed as the National Executive Sales Director of the Diabetes Portfolio Business Unit. Aihua Liu, the current head of the Oncology Portfolio Business Unit, will take over as the head of the Diabetes Alliance Business Unit. Both will report directly to Yifei Jiang, Vice President of Eli Lilly China's Diabetes Business Unit. This appointment will take effect from October 1.

Yuan Ping joined Eli Lilly in August 2009, holding positions such as Regional Sales Director, Head of Broad Market Sales, and National Sales Director for Oral Diabetes Medications at the Diabetes Alliance. In 2017, Yuan began serving as the National Sales Director of the Diabetes Alliance Division.

Liu Aihua joined Eli Lilly in 1996, serving successively as Regional Manager, Access Manager, Brand Manager, Regional Sales Director, National Sales Director, and Head of the CNS Division. In 2020, Liu Aihua was appointed as the Head of the Oncology Portfolio Division at Eli Lilly China.

Market value surges, breaking records twice

In the first half of this year, Eli Lilly and Company hadHas experiencedTwiceCityValueSurge.

On May 4, Eli Lilly announced positive results from the Phase 3 clinical trial of its investigational Alzheimer's disease drug Donanemab. The clinical results showed that Donanemab significantly slowed the decline in cognition and function in patients with early Alzheimer's disease.

Currently, there are over 55 million people living with dementia worldwide, and this number is expected to rise to nearly 139 million by 2050. Although the market potential is vast, Alzheimer's disease drug research has the highest failure rate among all drug studies, often referred to as a "research and development black hole."

Following the announcement of this research result, Eli Lilly's market value soared, making it the world's first pure pharmaceutical company to break through a market capitalization of 400 billion US dollars.

On August 8 this year, Eli Lilly and Company announced its Q2 financial report for 2023. The total revenue in the first half of the year reached $15.272 billion, representing a 7% year-on-year increase. Specifically, the revenue for the second quarter was $8.312 billion, marking a 28% year-on-year growth. In light of the better-than-expected growth demonstrated in its performance, Eli Lilly updated its financial guidance for the 2023 fiscal year, raising the company’s projected revenue by $2.2 billion to a range of $33.4-$33.9 billion.

Affected by this news, Eli Lilly's market value successfully broke through $500 billion, once again setting a new record for the market value of pure pharmaceutical enterprises.

Heavyweight Products Continue to Gain Momentum

The financial report shows that in the first half of this year, Eli Lilly's main growth came from products such as Mounjaro (Tirzepatide), Verzenio (Abemaciclib), Jardiance (Empagliflozin), and Taltz (Ixekizumab). Among them, the sales of Abemaciclib in the first half of the year were $1.678 billion, the sales of Empagliflozin were $1.246 billion, and the sales of Ixekizumab were $1.230 billion, all achieving不同程度的增长.

Notably, Eli Lilly's blockbuster product Tirzepatide generated $1.548 billion in sales in the first half of the year, with $980 million in sales achieved solely in the second quarter. Tirzepatide was approved for marketing in the U.S. on May 16 last year and has demonstrated strong potential within just four quarters. Eli Lilly anticipates that Tirzepatide’s total sales for this year will reach $4 billion.

In the Chinese market, according to the official website of the Center for Drug Evaluation under the National Medical Products Administration, the registration application for Tirzepatide Injection for long-term weight management in adult patients with obesity or overweight accompanied by at least one weight-related comorbidity, in addition to a low-calorie diet and increased exercise, has been officially accepted.

At the same time, Eli Lilly and Company is also increasing its efforts in mergers and acquisitions. On July 14 this year, Eli Lilly and Company announced the acquisition of Versanis Bio for $1.925 billion. It is reported that Versanis is developing a monoclonal antibody aimed at reducing fat mass without affecting muscle mass.